Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.
Last trade$1,708.18
Day change-$19.085 (-1.10%)
Day range$1,706.92 – $1,746.37
Volume58,276
Market cap$34.36B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$34.36B
Price / earnings
36.78×
Price / book
442.38×
Price / sales
8.18×
EV / sales
8.65×
EV / EBITDA
28.58×
Profitability
Earnings per share
$46.96
Return on assets
25.28%
Return on equity
1,202.75%
Dividend yield
0%
Liquidity and leverage
Debt / equity
26.06×
Current ratio
1.1×
Quick ratio
0.75×
Cash ratio
0.04×
Cash flow
Price / cash flow
34.9×
Price / free cash flow
39.46×
Free cash flow
$870.57M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MTD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.09B
$1.03B
$947.13M
$1.13B
$1.03B
$983.22M
$883.74M
$1.05B
Cost of revenue
$440.07M
$377.1M
$391.31M
$454.3M
$420.24M
$403.35M
$357.87M
$405.81M
Gross profit
$654.22M
$650.22M
$555.82M
$675.44M
$609.46M
$579.88M
$525.88M
$639.32M
Selling, general and administrative
$267.16M
$263.33M
$258.33M
$259.83M
$248.39M
$247.3M
$242.8M
$237.34M
Research and development
$53.61M
$52.99M
$51.28M
$52.6M
$51.14M
$49.29M
$46.35M
$50.05M
Total operating expenses
$344.09M
$341.2M
$336.48M
$336.67M
$325.53M
$317.72M
$310.11M
$307.76M
Operating income
$310.13M
$309.02M
$219.33M
$338.77M
$283.93M
$262.16M
$215.77M
$331.55M
Interest expense
-$15.68M
-$17.25M
-$17.01M
-$17.39M
-$17.7M
-$16.78M
-$16.65M
-$17.85M
Income before taxes
$300.2M
$289.4M
$209.66M
$329.07M
$269.24M
$248.66M
$201.94M
$314.55M
Income taxes
$54.25M
$56.5M
$40.2M
$43.31M
$51.74M
$46.31M
$38.36M
$62.25M
Net income
$245.95M
$232.9M
$169.45M
$285.77M
$217.49M
$202.35M
$163.59M
$252.3M
Net income attributable to common shareholders
$245.95M
$232.9M
$169.45M
$285.77M
$217.49M
$202.35M
$163.59M
$252.3M
EBITDA
$288.31M
$347.2M
$259.38M
$376.1M
$267.84M
$296.16M
$249.2M
$364.56M
Basic earnings per share
$12.32
$11.57
$8.35
$14.03
$10.60
$9.78
$7.84
$12.00
Diluted earnings per share
$12.29
$11.55
$8.33
$13.99
$10.57
$9.76
$7.81
$11.95
Recent news
Company coverage with links to the original publishers.
Mettler-Toledo reported Q3 2026 earnings of $12.57 per share, beating consensus estimates of $12.11, with revenues of $1.09 billion exceeding expectations by 2.28%. The company has outperformed the market by 23.6% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.
Veracyte reported Q3 2026 earnings of $0.51 per share, beating consensus estimates by 15.91%, with revenues of $151.75 million exceeding expectations by 3.06%. The company has outperformed market estimates in four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Instruments industry ranks in the top 43% of Zacks industries.
Mettler-Toledo is set to report Q3 2026 results on Nov. 5, with revenues estimated to grow 3.9% to $1.07 billion and EPS projected to increase 8.6% to $12.11. The company is expected to benefit from improving market conditions in China and emerging markets, strong demand for automation solutions, and contributions from recent acquisitions and the Spinnaker sales program.
Zacks highlights strong stock performance across its various investment portfolios in early November 2026. Marathon Petroleum gained 14.71% following a Zacks Rank upgrade, while Chevron and Cheniere Energy surged 22.5% and 28% respectively over 12 weeks. Amgen returned 20.2% over the same period as investors favor quality dividend stocks amid market volatility. The article showcases performance of Zacks' rating systems including the Rank #1 portfolio, Focus List, and specialized portfolios like ECAP and ECDP.
Mettler-Toledo, a precision instruments maker, has a strong track record of beating earnings estimates with an average surprise of 4.36% over the past two quarters. The company has a positive Earnings ESP of +0.10% combined with a Zacks Rank #3 (Hold), suggesting another earnings beat is likely when it reports on November 5, 2026. Stocks with this combination historically beat consensus estimates nearly 70% of the time.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.